SP-35454

SP-35454 is an investigational small molecule selective estrogen receptor modulator (SERM) developed by Shin Poong Pharmaceutical for the treatment of postmenopausal osteoporosis. As a SERM, SP-35454 is designed to exert tissue-specific effects, acting as an agonist in bone tissue to inhibit osteoclast activity and maintain bone mineral density, while potentially acting as an antagonist or having neutral effects in breast and uterine tissues to improve safety compared to traditional hormone replacement therapy. The compound has undergone Phase 1 clinical evaluation in healthy postmenopausal women to assess its safety, tolerability, and pharmacokinetic profile.